10-Baggas Factory 10

[$Pistol Pete$]

$PMCB Mr. Waggoner said of this opportunity, “This is good news for PharmaCyte shareholders since the change from an “exploratory” trial to a “pivotal” trial can eliminate one or two lengthy and costly trials and potentially make PharmaCyte’s Cell-in-a-Box®-based product, CypCaps™, “market-ready” in a much shorter period of time than anticipated. It may also accelerate the overall development timeline if the results are very positive, thus making the therapy more attractive to potential investors or suitors.”

https://globenewswire.com/news-release/2017/02/13/916491/0/en/PharmaCyte-Biotech-Moves-Closer-to-Filing-IND-with-Naming-of-Comparator-Arm-for-Upcoming-Clinical-Trial-and-Discusses-Pivotal-Trial-Opportunity.html



Go $PMCB